{
  "protocolSection": {
    "identificationModule": {
      "nctId": "NCT05188053",
      "orgStudyIdInfo": {
        "id": "21-010044"
      },
      "organization": {
        "fullName": "Mayo Clinic",
        "class": "OTHER"
      },
      "briefTitle": "Periarticular Bupivacaine + Meloxicam ER Solution Versus Standard Practice During Total Knee Arthroplasty",
      "officialTitle": "Periarticular Bupivacaine + Meloxicam ER Solution Versus Standard Practice During Total Knee Arthroplasty: A Single Institution, Single-blinded, Randomized Clinical Trial"
    },
    "statusModule": {
      "statusVerifiedDate": "2025-04",
      "overallStatus": "COMPLETED",
      "expandedAccessInfo": {
        "hasExpandedAccess": false
      },
      "startDateStruct": {
        "date": "2022-03-11",
        "type": "ACTUAL"
      },
      "primaryCompletionDateStruct": {
        "date": "2024-04-18",
        "type": "ACTUAL"
      },
      "completionDateStruct": {
        "date": "2024-04-18",
        "type": "ACTUAL"
      },
      "studyFirstSubmitDate": "2021-12-27",
      "studyFirstSubmitQcDate": "2022-01-11",
      "studyFirstPostDateStruct": {
        "date": "2022-01-12",
        "type": "ACTUAL"
      },
      "resultsFirstSubmitDate": "2025-03-07",
      "resultsFirstSubmitQcDate": "2025-04-11",
      "resultsFirstPostDateStruct": {
        "date": "2025-04-27",
        "type": "ACTUAL"
      },
      "lastUpdateSubmitDate": "2025-04-11",
      "lastUpdatePostDateStruct": {
        "date": "2025-04-27",
        "type": "ACTUAL"
      }
    },
    "sponsorCollaboratorsModule": {
      "responsibleParty": {
        "type": "PRINCIPAL_INVESTIGATOR",
        "investigatorFullName": "Matthew P. Abdel, M.D.",
        "investigatorTitle": "Principal Investigator",
        "investigatorAffiliation": "Mayo Clinic"
      },
      "leadSponsor": {
        "name": "Mayo Clinic",
        "class": "OTHER"
      }
    },
    "oversightModule": {
      "oversightHasDmc": false,
      "isFdaRegulatedDrug": true,
      "isFdaRegulatedDevice": false
    },
    "descriptionModule": {
      "briefSummary": "The purpose of this study is to compare an FDA-approved medication for post-operative pain control (HTX-011) to the standard of care institutional practice for periarticular analgesia after primary total knee arthroplasty (weight based dosing of Ropivacaine, epinephrine and ketorolac diluted with saline). We are doing this research study to find out if this new medication provides superior pain control within 72 hours following surgery."
    },
    "conditionsModule": {
      "conditions": [
        "Total Knee Arthroplasty"
      ]
    },
    "designModule": {
      "studyType": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "designInfo": {
        "allocation": "RANDOMIZED",
        "interventionModel": "PARALLEL",
        "primaryPurpose": "TREATMENT",
        "maskingInfo": {
          "masking": "SINGLE",
          "whoMasked": [
            "PARTICIPANT"
          ]
        }
      },
      "enrollmentInfo": {
        "count": 209,
        "type": "ACTUAL"
      }
    },
    "armsInterventionsModule": {
      "armGroups": [
        {
          "label": "HTX-011 Treatment Group",
          "type": "EXPERIMENTAL",
          "description": "Subjects undergoing a total knee arthroplasty will receive HTX-011 (Zynrelef) for perioperative analgesia",
          "interventionNames": [
            "Drug: HTX-011"
          ]
        },
        {
          "label": "Standard Block Control Group",
          "type": "ACTIVE_COMPARATOR",
          "description": "Subjects undergoing a total knee arthroplasty will receive standard of care arthroplasty block for perioperative analgesia",
          "interventionNames": [
            "Drug: ropivacaine , epinephrine , ketorolac diluted in sodium chloride"
          ]
        }
      ],
      "interventions": [
        {
          "type": "DRUG",
          "name": "HTX-011",
          "description": "Single dose administration periarticular 400mg bupivacaine and 12mg meloxicam extended release solution",
          "armGroupLabels": [
            "HTX-011 Treatment Group"
          ],
          "otherNames": [
            "Zynrelef"
          ]
        },
        {
          "type": "DRUG",
          "name": "ropivacaine , epinephrine , ketorolac diluted in sodium chloride",
          "description": "Single dose administration in 100cc of standard formulation, there is 225mg of ropivacaine 5mg/mL, 0.6mg epinephrine 1mg/mL, 30mg ketorolac 30mg/mL diluted in sodium chloride",
          "armGroupLabels": [
            "Standard Block Control Group"
          ],
          "otherNames": [
            "Mayo Clinic standard arthroplasty block"
          ]
        }
      ]
    },
    "outcomesModule": {
      "primaryOutcomes": [
        {
          "measure": "Pain Control at 72 Hours Postoperatively",
          "description": "Area Under the Curve (AUC) of the graph for mean Numerical Rated Score (NRS) for pain (0-10) over time (0-72 hours) / NRS AUC 0-72. Pain scores were collected by patient self-report 15 times over the 72 hours after surgery, and averaged amongst the patients for each study arm.\n\nLower values represent better pain control based on lower mean 0-10 pain scores over the 72 hour period after surgery. The minimum value is 0, meaning patients reported 0 pain on a 0-10 scale at all 15 time points within 72 hours. The maximum value would be 720, meaning patients reported a 10 for pain on a 0-10 scale at all 15 time points within 72 hours.",
          "timeFrame": "72-hours postoperatively after total knee arthroplasty"
        }
      ],
      "secondaryOutcomes": [
        {
          "measure": "Pain Control at 48 Hours Postoperatively",
          "description": "Area Under the Curve (AUC) of the graph for mean Numerical Rated Score (NRS) for pain (0-10) over time (0-48 hours) / NRS AUC 0-48. Pain scores were collected by patient self-report 11 times over the 48 hours after surgery, and averaged amongst the patients for each study arm.\n\nLower values represent better pain control based on lower mean 0-10 pain scores over the 48 hour period after surgery. The minimum value is 0, meaning patients reported 0 pain on a 0-10 scale at all 11 time points within 48 hours. The maximum value would be 480, meaning patients reported a 10 for pain on a 0-10 scale at all 11 time points within 48 hours",
          "timeFrame": "48-hours postoperative total knee arthroplasty"
        },
        {
          "measure": "Opioid Consumption 72 Hours Postoperatively",
          "description": "Total postoperative opioid consumption standardized into morphine milligram equivalents (MMEs)",
          "timeFrame": "72-hours postoperative total knee arthroplasty"
        },
        {
          "measure": "Opioid Consumption 48 Hours Postoperatively",
          "description": "Total postoperative opioid consumption standardized into morphine milligram equivalents (MMEs)",
          "timeFrame": "48 hours postoperative total knee arthroplasty"
        }
      ]
    },
    "eligibilityModule": {
      "eligibilityCriteria": "Inclusion Criteria:\n\n* ASA classification I to III, older than or equal to 18 years old.\n* Presenting for primary total knee replacement for degenerative joint disease.\n* Patient capable of providing their own informed consent.\n\nExclusion Criteria:\n\n* Vulnerable study populations including prisoners.\n* Patients with a contralateral total knee arthroplasty \\< 2 years prior to the index procedure.\n* Compromised health barring them from proceeding with surgery including acute or chronic kidney injury identified pre-operative.\n* Patients unable to provide their own informed consent.\n* Pregnancy.\n* Patients with documented chronic pain syndromes.\n* Patients with a history of prolonged daily opioids (more than 1 month) with an oral morphine equivalent of greater than 5mg/day.\n* BMI \\> 45 kg/m\\^2.\n* Allergies to any component of the study medications, including specific history of type 1 hypersensitivities to any NSAID.\n* Patients with impaired cognitive function.\n* Major systemic illnesses such as severe renal (estimated glomerular filtration rate less than 50ml/min), coronary artery disease requiring a bypass graft (CABG), other cardiac problems including congestive heart failure (CHF New York Heart Association class III to IV), or severe hepatic disorders defined as current or past diagnosis of acute/subacute liver necrosis, acute hepatic failure, chronic liver disease, liver abscess, hepatic coma, hepatorenal syndrome and other disorders of the liver.",
      "healthyVolunteers": false,
      "sex": "ALL",
      "minimumAge": "18 Years",
      "stdAges": [
        "ADULT",
        "OLDER_ADULT"
      ]
    },
    "contactsLocationsModule": {
      "overallOfficials": [
        {
          "name": "Matthew P Abdel, MD",
          "affiliation": "Mayo Clinic",
          "role": "PRINCIPAL_INVESTIGATOR"
        }
      ],
      "locations": [
        {
          "facility": "Mayo Clinic in Rochester",
          "city": "Rochester",
          "state": "Minnesota",
          "zip": "55905",
          "country": "United States",
          "geoPoint": {
            "lat": 44.02163,
            "lon": -92.4699
          }
        }
      ]
    },
    "referencesModule": {
      "seeAlsoLinks": [
        {
          "label": "Mayo Clinic Clinical Trials",
          "url": "https://www.mayo.edu/research/clinical-trials"
        }
      ]
    }
  },
  "resultsSection": {
    "participantFlowModule": {
      "preAssignmentDetails": "An initial pilot of 18 patients ran from 3/11/2022 to 8/30/2022 after which a protocol change caused these patients to be withdrawn and not assigned to a treatment arm in the final study count. One additional patient was withdrawn prior to randomization as allergy results returned which excluded participation.",
      "recruitmentDetails": "Recruitment for this study ran from 3/11/2022 until 4/9/2024 when the final patient was enrolled. Patients were enrolled from the Orthopedic clinical practice at Mayo Clinic.",
      "groups": [
        {
          "id": "FG000",
          "title": "HTX-011 Treatment Group",
          "description": "Subjects undergoing a total knee arthroplasty will receive HTX-011 (Zynrelef) for perioperative analgesia\n\nHTX-011: Single dose administration periarticular 400mg bupivacaine and 12mg meloxicam extended release solution"
        },
        {
          "id": "FG001",
          "title": "Standard Block Control Group",
          "description": "Subjects undergoing a total knee arthroplasty will receive standard of care arthroplasty block for perioperative analgesia\n\nropivacaine , epinephrine , ketorolac diluted in sodium chloride: Single dose administration in 100cc of standard formulation, there is 225mg of ropivacaine 5mg/mL, 0.6mg epinephrine 1mg/mL, 30mg ketorolac 30mg/mL diluted in sodium chloride"
        }
      ],
      "periods": [
        {
          "title": "Overall Study",
          "milestones": [
            {
              "type": "STARTED",
              "achievements": [
                {
                  "groupId": "FG000",
                  "numSubjects": "95"
                },
                {
                  "groupId": "FG001",
                  "numSubjects": "95"
                }
              ]
            },
            {
              "type": "COMPLETED",
              "achievements": [
                {
                  "groupId": "FG000",
                  "numSubjects": "53"
                },
                {
                  "groupId": "FG001",
                  "numSubjects": "48"
                }
              ]
            },
            {
              "type": "NOT COMPLETED",
              "achievements": [
                {
                  "groupId": "FG000",
                  "numSubjects": "42"
                },
                {
                  "groupId": "FG001",
                  "numSubjects": "47"
                }
              ]
            }
          ],
          "dropWithdraws": [
            {
              "type": "Lost to Follow-up",
              "reasons": [
                {
                  "groupId": "FG000",
                  "numSubjects": "23"
                },
                {
                  "groupId": "FG001",
                  "numSubjects": "30"
                }
              ]
            },
            {
              "type": "Protocol Violation",
              "reasons": [
                {
                  "groupId": "FG000",
                  "numSubjects": "16"
                },
                {
                  "groupId": "FG001",
                  "numSubjects": "16"
                }
              ]
            },
            {
              "type": "Physician Decision",
              "reasons": [
                {
                  "groupId": "FG000",
                  "numSubjects": "3"
                },
                {
                  "groupId": "FG001",
                  "numSubjects": "0"
                }
              ]
            },
            {
              "type": "Withdrawal by Subject",
              "reasons": [
                {
                  "groupId": "FG000",
                  "numSubjects": "0"
                },
                {
                  "groupId": "FG001",
                  "numSubjects": "1"
                }
              ]
            }
          ]
        }
      ]
    },
    "baselineCharacteristicsModule": {
      "groups": [
        {
          "id": "BG000",
          "title": "HTX-011 Treatment Group",
          "description": "Subjects undergoing a total knee arthroplasty will receive HTX-011 (Zynrelef) for perioperative analgesia\n\nHTX-011: Single dose administration periarticular 400mg bupivacaine and 12mg meloxicam extended release solution"
        },
        {
          "id": "BG001",
          "title": "Standard Block Control Group",
          "description": "Subjects undergoing a total knee arthroplasty will receive standard of care arthroplasty block for perioperative analgesia\n\nropivacaine , epinephrine , ketorolac diluted in sodium chloride: Single dose administration in 100cc of standard formulation, there is 225mg of ropivacaine 5mg/mL, 0.6mg epinephrine 1mg/mL, 30mg ketorolac 30mg/mL diluted in sodium chloride"
        },
        {
          "id": "BG002",
          "title": "Total",
          "description": "Total of all reporting groups"
        }
      ],
      "denoms": [
        {
          "units": "Participants",
          "counts": [
            {
              "groupId": "BG000",
              "value": "95"
            },
            {
              "groupId": "BG001",
              "value": "95"
            },
            {
              "groupId": "BG002",
              "value": "190"
            }
          ]
        }
      ],
      "measures": [
        {
          "title": "Age, Continuous",
          "paramType": "MEAN",
          "dispersionType": "STANDARD_DEVIATION",
          "unitOfMeasure": "years",
          "classes": [
            {
              "denoms": [
                {
                  "units": "Participants",
                  "counts": [
                    {
                      "groupId": "BG000",
                      "value": "95"
                    },
                    {
                      "groupId": "BG001",
                      "value": "95"
                    },
                    {
                      "groupId": "BG002",
                      "value": "190"
                    }
                  ]
                }
              ],
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "69.6",
                      "spread": "8.1"
                    },
                    {
                      "groupId": "BG001",
                      "value": "69.9",
                      "spread": "8.6"
                    },
                    {
                      "groupId": "BG002",
                      "value": "69.7",
                      "spread": "8.3"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "title": "Sex: Female, Male",
          "paramType": "COUNT_OF_PARTICIPANTS",
          "unitOfMeasure": "Participants",
          "classes": [
            {
              "denoms": [
                {
                  "units": "Participants",
                  "counts": [
                    {
                      "groupId": "BG000",
                      "value": "95"
                    },
                    {
                      "groupId": "BG001",
                      "value": "95"
                    },
                    {
                      "groupId": "BG002",
                      "value": "190"
                    }
                  ]
                }
              ],
              "categories": [
                {
                  "title": "Female",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "54"
                    },
                    {
                      "groupId": "BG001",
                      "value": "54"
                    },
                    {
                      "groupId": "BG002",
                      "value": "108"
                    }
                  ]
                },
                {
                  "title": "Male",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "41"
                    },
                    {
                      "groupId": "BG001",
                      "value": "41"
                    },
                    {
                      "groupId": "BG002",
                      "value": "82"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "title": "Race and Ethnicity Not Collected",
          "populationDescription": "Race and Ethnicity were not collected from any participant.",
          "paramType": "COUNT_OF_PARTICIPANTS",
          "unitOfMeasure": "Participants",
          "classes": [
            {
              "denoms": [
                {
                  "units": "Participants",
                  "counts": [
                    {
                      "groupId": "BG000",
                      "value": "0"
                    },
                    {
                      "groupId": "BG001",
                      "value": "0"
                    },
                    {
                      "groupId": "BG002",
                      "value": "0"
                    }
                  ]
                }
              ],
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "BG002",
                      "value": "0"
                    }
                  ]
                }
              ]
            }
          ]
        }
      ]
    },
    "outcomeMeasuresModule": {
      "outcomeMeasures": [
        {
          "type": "PRIMARY",
          "title": "Pain Control at 72 Hours Postoperatively",
          "description": "Area Under the Curve (AUC) of the graph for mean Numerical Rated Score (NRS) for pain (0-10) over time (0-72 hours) / NRS AUC 0-72. Pain scores were collected by patient self-report 15 times over the 72 hours after surgery, and averaged amongst the patients for each study arm.\n\nLower values represent better pain control based on lower mean 0-10 pain scores over the 72 hour period after surgery. The minimum value is 0, meaning patients reported 0 pain on a 0-10 scale at all 15 time points within 72 hours. The maximum value would be 720, meaning patients reported a 10 for pain on a 0-10 scale at all 15 time points within 72 hours.",
          "reportingStatus": "POSTED",
          "paramType": "MEAN",
          "dispersionType": "Standard Deviation",
          "unitOfMeasure": "score on a scale * hours",
          "timeFrame": "72-hours postoperatively after total knee arthroplasty",
          "groups": [
            {
              "id": "OG000",
              "title": "HTX-011 Treatment Group",
              "description": "Subjects undergoing a total knee arthroplasty will receive HTX-011 (Zynrelef) for perioperative analgesia\n\nHTX-011: Single dose administration periarticular 400mg bupivacaine and 12mg meloxicam extended release solution"
            },
            {
              "id": "OG001",
              "title": "Standard Block Control Group",
              "description": "Subjects undergoing a total knee arthroplasty will receive standard of care arthroplasty block for perioperative analgesia\n\nropivacaine , epinephrine , ketorolac diluted in sodium chloride: Single dose administration in 100cc of standard formulation, there is 225mg of ropivacaine 5mg/mL, 0.6mg epinephrine 1mg/mL, 30mg ketorolac 30mg/mL diluted in sodium chloride"
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "53"
                },
                {
                  "groupId": "OG001",
                  "value": "48"
                }
              ]
            }
          ],
          "classes": [
            {
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "334",
                      "spread": "16"
                    },
                    {
                      "groupId": "OG001",
                      "value": "370",
                      "spread": "21"
                    }
                  ]
                }
              ]
            }
          ],
          "analyses": [
            {
              "groupIds": [
                "OG000",
                "OG001"
              ],
              "groupDescription": "Two-sample t-test with unequal variance. The null hypothesis is that there was no statistically significant difference between the two treatment groups based on a standard alpha value of 0.05.",
              "nonInferiorityType": "OTHER",
              "nonInferiorityComment": "Sample size calculations were performed to estimate the number of subjects needed to detect a 30% difference in NRS pain AUC scores between the study groups.\n\n30% reduction in pain was considered the minimal clinically important difference in pain control based off previous pain research.\n\nA 30% reduction in pain would correspond with a difference of approximately 136 in area under the curve of mean pain over time.",
              "pValue": "0.170",
              "pValueComment": "a priori threshold p \\<0.05",
              "statisticalMethod": "t-test, 2 sided",
              "statisticalComment": "assuming unequal variance"
            }
          ]
        },
        {
          "type": "SECONDARY",
          "title": "Pain Control at 48 Hours Postoperatively",
          "description": "Area Under the Curve (AUC) of the graph for mean Numerical Rated Score (NRS) for pain (0-10) over time (0-48 hours) / NRS AUC 0-48. Pain scores were collected by patient self-report 11 times over the 48 hours after surgery, and averaged amongst the patients for each study arm.\n\nLower values represent better pain control based on lower mean 0-10 pain scores over the 48 hour period after surgery. The minimum value is 0, meaning patients reported 0 pain on a 0-10 scale at all 11 time points within 48 hours. The maximum value would be 480, meaning patients reported a 10 for pain on a 0-10 scale at all 11 time points within 48 hours",
          "reportingStatus": "POSTED",
          "paramType": "MEAN",
          "dispersionType": "Standard Deviation",
          "unitOfMeasure": "score on a scale * hours",
          "timeFrame": "48-hours postoperative total knee arthroplasty",
          "groups": [
            {
              "id": "OG000",
              "title": "HTX-011 Treatment Group",
              "description": "Subjects undergoing a total knee arthroplasty will receive HTX-011 (Zynrelef) for perioperative analgesia\n\nHTX-011: Single dose administration periarticular 400mg bupivacaine and 12mg meloxicam extended release solution"
            },
            {
              "id": "OG001",
              "title": "Standard Block Control Group",
              "description": "Subjects undergoing a total knee arthroplasty will receive standard of care arthroplasty block for perioperative analgesia\n\nropivacaine , epinephrine , ketorolac diluted in sodium chloride: Single dose administration in 100cc of standard formulation, there is 225mg of ropivacaine 5mg/mL, 0.6mg epinephrine 1mg/mL, 30mg ketorolac 30mg/mL diluted in sodium chloride"
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "53"
                },
                {
                  "groupId": "OG001",
                  "value": "48"
                }
              ]
            }
          ],
          "classes": [
            {
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "237",
                      "spread": "14"
                    },
                    {
                      "groupId": "OG001",
                      "value": "268",
                      "spread": "13"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "type": "SECONDARY",
          "title": "Opioid Consumption 72 Hours Postoperatively",
          "description": "Total postoperative opioid consumption standardized into morphine milligram equivalents (MMEs)",
          "populationDescription": "patient who returned a complete pain diary",
          "reportingStatus": "POSTED",
          "paramType": "MEAN",
          "dispersionType": "Full Range",
          "unitOfMeasure": "MME",
          "timeFrame": "72-hours postoperative total knee arthroplasty",
          "groups": [
            {
              "id": "OG000",
              "title": "HTX-011 Treatment Group",
              "description": "Subjects undergoing a total knee arthroplasty will receive HTX-011 (Zynrelef) for perioperative analgesia\n\nHTX-011: Single dose administration periarticular 400mg bupivacaine and 12mg meloxicam extended release solution"
            },
            {
              "id": "OG001",
              "title": "Standard Block Control Group",
              "description": "Subjects undergoing a total knee arthroplasty will receive standard of care arthroplasty block for perioperative analgesia\n\nropivacaine , epinephrine , ketorolac diluted in sodium chloride: Single dose administration in 100cc of standard formulation, there is 225mg of ropivacaine 5mg/mL, 0.6mg epinephrine 1mg/mL, 30mg ketorolac 30mg/mL diluted in sodium chloride"
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "53"
                },
                {
                  "groupId": "OG001",
                  "value": "48"
                }
              ]
            }
          ],
          "classes": [
            {
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "85",
                      "lowerLimit": "0",
                      "upperLimit": "238"
                    },
                    {
                      "groupId": "OG001",
                      "value": "77",
                      "lowerLimit": "0",
                      "upperLimit": "163"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "type": "SECONDARY",
          "title": "Opioid Consumption 48 Hours Postoperatively",
          "description": "Total postoperative opioid consumption standardized into morphine milligram equivalents (MMEs)",
          "populationDescription": "patients who returned a completed pain diary",
          "reportingStatus": "POSTED",
          "paramType": "MEAN",
          "dispersionType": "Full Range",
          "unitOfMeasure": "MME",
          "timeFrame": "48 hours postoperative total knee arthroplasty",
          "groups": [
            {
              "id": "OG000",
              "title": "HTX-011 Treatment Group",
              "description": "Subjects undergoing a total knee arthroplasty will receive HTX-011 (Zynrelef) for perioperative analgesia\n\nHTX-011: Single dose administration periarticular 400mg bupivacaine and 12mg meloxicam extended release solution"
            },
            {
              "id": "OG001",
              "title": "Standard Block Control Group",
              "description": "Subjects undergoing a total knee arthroplasty will receive standard of care arthroplasty block for perioperative analgesia\n\nropivacaine , epinephrine , ketorolac diluted in sodium chloride: Single dose administration in 100cc of standard formulation, there is 225mg of ropivacaine 5mg/mL, 0.6mg epinephrine 1mg/mL, 30mg ketorolac 30mg/mL diluted in sodium chloride"
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "53"
                },
                {
                  "groupId": "OG001",
                  "value": "48"
                }
              ]
            }
          ],
          "classes": [
            {
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "67",
                      "lowerLimit": "0",
                      "upperLimit": "163"
                    },
                    {
                      "groupId": "OG001",
                      "value": "60",
                      "lowerLimit": "0",
                      "upperLimit": "182"
                    }
                  ]
                }
              ]
            }
          ]
        }
      ]
    },
    "adverseEventsModule": {
      "frequencyThreshold": "0",
      "timeFrame": "Adverse event data was collected from patient consent until 72 hours postoperatively.",
      "eventGroups": [
        {
          "id": "EG000",
          "title": "HTX-011 Treatment Group",
          "description": "Subjects undergoing a total knee arthroplasty will receive HTX-011 (Zynrelef) for perioperative analgesia\n\nHTX-011: Single dose administration periarticular 400mg bupivacaine and 12mg meloxicam extended release solution",
          "deathsNumAffected": 0,
          "deathsNumAtRisk": 53,
          "seriousNumAffected": 0,
          "seriousNumAtRisk": 53,
          "otherNumAffected": 1,
          "otherNumAtRisk": 53
        },
        {
          "id": "EG001",
          "title": "Standard Block Control Group",
          "description": "Subjects undergoing a total knee arthroplasty will receive standard of care arthroplasty block for perioperative analgesia\n\nropivacaine , epinephrine , ketorolac diluted in sodium chloride: Single dose administration in 100cc of standard formulation, there is 225mg of ropivacaine 5mg/mL, 0.6mg epinephrine 1mg/mL, 30mg ketorolac 30mg/mL diluted in sodium chloride",
          "deathsNumAffected": 0,
          "deathsNumAtRisk": 48,
          "seriousNumAffected": 0,
          "seriousNumAtRisk": 48,
          "otherNumAffected": 2,
          "otherNumAtRisk": 48
        }
      ],
      "otherEvents": [
        {
          "term": "Nausea",
          "organSystem": "Gastrointestinal disorders",
          "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
          "notes": "Stomach distress or discomfort with a possible urge to vomit.",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 53
            },
            {
              "groupId": "EG001",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 48
            }
          ]
        },
        {
          "term": "Seizure",
          "organSystem": "Nervous system disorders",
          "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
          "notes": "A sudden burst of electrical activity in the brain possibly causing changes in behavior, movements, feelings and levels of consciousness",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 53
            },
            {
              "groupId": "EG001",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 48
            }
          ]
        }
      ]
    },
    "moreInfoModule": {
      "certainAgreement": {
        "piSponsorEmployee": true
      },
      "pointOfContact": {
        "title": "Gabriel Schouten - Clinical Research Coordinator",
        "organization": "Mayo Clinic",
        "email": "schouten.gabriel@mayo.edu",
        "phone": "507-266-5895"
      }
    }
  },
  "documentSection": {
    "largeDocumentModule": {
      "largeDocs": [
        {
          "typeAbbrev": "Prot_SAP",
          "hasProtocol": true,
          "hasSap": true,
          "hasIcf": false,
          "label": "Study Protocol and Statistical Analysis Plan",
          "date": "2024-01-29",
          "uploadDate": "2025-03-04T17:48",
          "filename": "Prot_SAP_000.pdf",
          "size": 690868
        }
      ]
    }
  },
  "derivedSection": {
    "miscInfoModule": {
      "versionHolder": "2025-12-02",
      "submissionTracking": {
        "firstMcpInfo": {
          "postDateStruct": {
            "date": "2025-03-25",
            "type": "ACTUAL"
          }
        }
      }
    },
    "interventionBrowseModule": {
      "meshes": [
        {
          "id": "C000723006",
          "term": "bupivacaine-meloxicam drug combination"
        },
        {
          "id": "D000077212",
          "term": "Ropivacaine"
        },
        {
          "id": "D004837",
          "term": "Epinephrine"
        },
        {
          "id": "D012965",
          "term": "Sodium Chloride"
        }
      ],
      "ancestors": [
        {
          "id": "D000813",
          "term": "Anilides"
        },
        {
          "id": "D000577",
          "term": "Amides"
        },
        {
          "id": "D009930",
          "term": "Organic Chemicals"
        },
        {
          "id": "D000814",
          "term": "Aniline Compounds"
        },
        {
          "id": "D000588",
          "term": "Amines"
        },
        {
          "id": "D004983",
          "term": "Ethanolamines"
        },
        {
          "id": "D000605",
          "term": "Amino Alcohols"
        },
        {
          "id": "D000438",
          "term": "Alcohols"
        },
        {
          "id": "D015306",
          "term": "Biogenic Monoamines"
        },
        {
          "id": "D001679",
          "term": "Biogenic Amines"
        },
        {
          "id": "D002395",
          "term": "Catecholamines"
        },
        {
          "id": "D002396",
          "term": "Catechols"
        },
        {
          "id": "D010636",
          "term": "Phenols"
        },
        {
          "id": "D001555",
          "term": "Benzene Derivatives"
        },
        {
          "id": "D006841",
          "term": "Hydrocarbons, Aromatic"
        },
        {
          "id": "D006844",
          "term": "Hydrocarbons, Cyclic"
        },
        {
          "id": "D006838",
          "term": "Hydrocarbons"
        },
        {
          "id": "D002712",
          "term": "Chlorides"
        },
        {
          "id": "D006851",
          "term": "Hydrochloric Acid"
        },
        {
          "id": "D017606",
          "term": "Chlorine Compounds"
        },
        {
          "id": "D007287",
          "term": "Inorganic Chemicals"
        },
        {
          "id": "D017670",
          "term": "Sodium Compounds"
        }
      ]
    }
  },
  "hasResults": true
}